Instil Bio, Inc. (TIL) closed the last trading session at $34.23, gaining 134% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $118.67 indicates a 246.7% upside potential.The average comprises three short-term price targets ranging from a low of $51 to a high of $180, with a standard deviation of $64.73. While the lowest estimate indicates an increase of 49% from the current price ...

DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Instil's wholly-owned subsidiary dedicated to the development of AXN-2510 ("'2510"), a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer (NSCLC). About Ax ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization. Bronson Crouch, CEO of ...

DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson Crouch, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference at 4:20PM ET on Thursday, June 5, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/jeff319/til/1708376. About Instil BioInstil Bio is a clinical-stage biopharmaceutical company f ...

Instil Bio, Inc. (TIL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earni ...

Instil Bio, Inc. (TIL) closed the last trading session at $26.75, gaining 108.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $118.67 indicates a 343.6% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $64.73. While the lowest estimate of $51 indicates a 90.7% increase from the current price level, the most optimistic analy ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center. Instil and ImmuneOnco management, along with a key opinion leader in the field of immuno-oncology, will discuss the evolving PD-(L ...

Financial Performance - For the three months ended March 31, 2025, the net loss was $28.2 million, compared to a net loss of $24.3 million for the same period in 2024, representing an increase of $3.9 million [100]. - Total operating expenses for the three months ended March 31, 2025, were $30.6 million, an increase of $6.6 million from $24.0 million in the same period in 2024 [118]. - Cash used in operating activities for the three months ended March 31, 2025, was $4.2 million, compared to $14.4 million for the same period in 2024, indicating a significant reduction in cash outflow [140][141]. - The company has incurred significant operating losses and does not expect to generate revenue from product sales for several years [123]. Expenses Breakdown - Research and development expenses decreased to $5.4 million for the three months ended March 31, 2025, from $7.3 million in 2024, a reduction of $1.9 million [119]. - General and administrative expenses were $9.1 million for the three months ended March 31, 2025, down from $12.4 million in 2024, a decrease of $3.3 million [121]. - Restructuring and impairment charges increased to approximately $16.1 million for the three months ended March 31, 2025, compared to $4.3 million in 2024, an increase of approximately $11.8 million [121]. Cash and Investments - As of March 31, 2025, the company had cash, cash equivalents, restricted cash, marketable securities, and long-term investments totaling $111.8 million [100]. - As of March 31, 2025, the company had cash and cash equivalents of $15.4 million, restricted cash of approximately $1.0 million, marketable securities of $88.3 million, and long-term investments of $7.2 million, totaling $111.8 million [124]. - Cash provided by investing activities for the three months ended March 31, 2025, was $9.6 million, primarily from marketable securities redemptions [142]. Financing Activities - The company raised net cash proceeds of $339.0 million from its IPO in the first quarter of 2021, selling 920,000 shares of common stock [125]. - The company entered into a Term Loan Agreement for $85.6 million to refinance construction loans, with a fixed interest rate of 6.35% per annum [127]. - Cash provided by financing activities for Q1 2025 was $0.2 million, primarily from stock options exercise of $0.4 million, offset by loan closing costs of $0.2 million [143]. - Cash provided by financing activities for Q1 2024 was nil, indicating no financing activities during that period [144]. Future Outlook - The company expects to continue incurring net losses for the foreseeable future due to ongoing development efforts [100]. - The company plans to pursue additional therapeutic in-licensing or acquisition opportunities to expand its pipeline [101]. - The company plans to sell the Tarzana facility, which could extend its cash runway if successful [132]. Regulatory and Reporting Status - The company is classified as an "emerging growth company," allowing it to rely on certain exemptions from public company reporting requirements until at least December 31, 2026 [150]. - The company may continue to be a "smaller reporting company" if the market value of shares held by non-affiliates remains below $250 million or if annual revenue is less than $100 million [151]. - The company has opted to delay adopting new accounting standards until it is no longer classified as an emerging growth company [149]. - The company’s financial statements may not be comparable to those of companies that comply with new accounting pronouncements as of public company effective dates [149]. - The management's discussion and analysis is based on GAAP-compliant condensed consolidated financial statements, requiring estimates and assumptions that may differ from actual results [145]. - The company is not required to provide quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company [152]. Product Development - The lead product candidate, AXN-2510/IMM2510, is a bispecific antibody targeting PD-L1 and VEGFs, currently in clinical trials for multiple solid tumor cancers [95]. - Over 100 patients have been enrolled in the Phase I trial of AXN-2510/IMM2510 as monotherapy for advanced solid tumors as of January 13, 2025 [97]. - The company made an upfront payment of $10.0 million to ImmuneOnco as part of a collaboration agreement, with potential future payments of up to $2.1 billion in milestones [134].